Cantor Fitzgerald Initiates Coverage On Artiva Biotherapeutics with Overweight Rating, Announces Price Target of $23
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has initiated coverage on Artiva Biotherapeutics (NASDAQ:ARTV) with an Overweight rating and a price target of $23.
August 13, 2024 | 11:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has initiated coverage on Artiva Biotherapeutics with an Overweight rating and a price target of $23.
The initiation of coverage with an Overweight rating and a price target of $23 by a reputable firm like Cantor Fitzgerald is likely to positively impact the stock price of Artiva Biotherapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100